

R1.126

~~16.~~
~~69.~~

¹⁵

The method of claim ~~68~~¹⁵ wherein the protein which is competent to transport potassium across a membrane is human.

R1.126

~~17.~~
~~70.~~

¹⁵

The method of claim ~~68~~¹⁵ wherein the cell expressing the potassium transport protein is transformed with a self replicating vector comprising a nucleic acid sequence encoding a mammalian protein comprising 2 P domains and 4 transmembrane segments, which protein is competent to transport potassium across a membrane.

R1.126

~~18.~~
~~71.~~

¹⁷

The method of claim ~~70~~¹⁷ wherein the self replicating vector comprises a nucleic acid sequence encoding a human potassium transport protein.

R1.126

~~19.~~
~~72.~~

¹⁸

The method of claim ~~71~~¹⁸ wherein the self replicating vector comprises SEQ ID. No. 1.

R1.126

~~20.~~
~~73.~~

¹⁵

A substance, identified by the method of claim ~~68~~¹⁵, which is capable of positively or negatively influencing the transport activity of a potassium transport channel.

R1.126

~~21.~~
~~74.~~

²⁰

The substance of claim ~~73~~²⁰ which influences the transport activity of the potassium transport channel comprising 2 P domains and 4 transmembrane segments.

R1.126

~~22.~~
~~75.~~

²¹

The substance of claim ~~74~~²¹ which influences the transport activity of the potassium transport channel represented by SEQ ID. No. 2.

R1.126

~~23.~~
~~76.~~

A pharmaceutical composition for the treatment of diseases caused by the malfunction of a potassium transport channel, comprising the substance of claim ~~73~~²⁰.